Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals, Inc. made a total of 3 dividend payments.
The sum of all dividends (adjusted for stock splits) is : $1.02
Date | Dividend | Adj Dividend |
---|---|---|
March 28, 18 | $0.42 | $0.42 |
December 28, 17 | $0.36 | $0.36 |
September 28, 17 | $0.24 | $0.24 |